SOVREMENNAYA PEDIATRIYA.2018.2(90):47-51; doi 10.15574/SP.2018.90.47

Mukvich O. M., Lavrenchuk O. V.
SI «Institute of Pediatrics, Obstetrics and Gynaecology of NAMS of Ukraine», Kyiv
Communal Non–profit Establishment «Primary Health Care Centre No.1 of Shevchenkivskyi Raion», Kyiv, Ukraine

Objective — to investigate the features of clinical course and immunological indicators of mucociliary barrier based on the β-defensin-2 (HBD-2) and immunoglobulin A, G, sIgA concentrations in saliva and coprofiltrates in children with chronic gastroduodenitis (CGD) and connective tissue dysplasia (CTD).
Material and methods. 127 patients aged 11–17 years were examined, 63 of them had H. Рilory–associated CGD in the incomplete remission after eradication therapy against a background of different grade CTD.
Results. CGD against a background of CTD is characterized by an early onset with frequent seasonal exacerbations and moderate-to-severe symptoms of non-specific intoxication, and dyspeptic signs with moderate abdominal pain syndrome. Certain local immune indicators in saliva and coprofiltrates (HBD-2, immunoglobulins sIgA, IgA, and IgG) in children with CGD were significantly higher, compared with a control group, due to the inflammation, while the same indicators were significantly lower in children with CGD against a background of CTD.
Conclusions. CGD burdened by CTD is observed at an earlier age (р<0.05) with an aggressive and progradient course with yearly seasonal exacerbations, relapses, and the moderate prolonged nagging abdominal pain syndrome, characterised by indistinct localization of pain centres. These symptoms are combined with severe symptoms of non-specific intoxication. The local immunity indices in saliva and coprofiltrates (HBD-2, immunoglobulins sIgA, IgA, IgG) for children without dysplastic manifestations (p<0.05) were decreased, which was precipitating factor for the course of pathological processes in patients with co-pathology.
Key words: children, chronic gastroduodenitis, connective tissue dysplasia, immunoglobulins, antimicrobial peptides (HBD-2).

References

1. Abbakumova LN. (2006). Connective tissue dysplasia. St Petersburg: 36.

2. Beketova GV. (2012). Chronic gastroduodenitis in children and adolescents: epidemiology, etiology, pathogenesis, diagnosis (part I). Ditiachii likar. 6: 20–24.

3. Bodnar GB. (2011). Research of immunity at patients with Helikobakter-associated by gastroduodenum pathology to the children. Sovremennaya Pediatriya. 3: 126–128.

4. Vernygorodskyi SV. (2014). Structural changes of the mucous membrane of the stomach and their peculiarities in chronic gastritis. Nauka molodyx – Eruditio juvenium. 1: 37–43.

5. Zavhorodnia NYu. (2012). Beta-defensins in the local anti-helicobacteric protection of stomach mucous membrane in children. Zdorove rebenka. 4(39): 30–34.

6. Kadurina TI, Ghorbunov VN. (2009). Connective tissue dysplasia. St Petersburg: Elbi.

7. Kondrashova VGh, Kolpakov IYe, Vdovenko VYu, Ghritsenko TV, Shepeliuk TV, Studenikina OM, Stepanova YeI. (2014). Clinical and anamnestic features of the gastrointestinal tract pathology in children with syndrome of heart connective tissue dysplasia, born from parents affected by the Chernobyl Power Plant accident in their childhood. Zdorove rebenka. 6: 57–60.

8. Kuznetsova LV, Karpova TA, Tiukacheva VYu. (2011). Chronic gastroduodenitis in the structure of connective tissue dysplasia syndrome in children. Pediatric aspects of connective tissue dysplasia. Achievements and prospects: Russian collection of scientific papers with international participation. Vol. 2. SF Ghnusaeva, TI Kadurinoi, AN. Semiachkinoi (Eds). Moskow, Tver, St Petersburg: RGh «РRЕ100»: 195–204.

9. Omelchenko LI, Oshlianskaia EA. (2009). Effect of phytopreparations on certain immune system indicators in children with connective tissue dysplasia. Sovremennaia pediatriia. 5: 43–48.

10. Defining unified protocols of medical assistance to children with digestive system diseases. Ministry of Health order No.59 of 29-01-2013. http://www.moz.gov.ua.

11. Sichinava I, Gorelov I, Shershevskaya A. (2011). Pathomorphism of chronic gastritis (gastroduodenitis) in children within 6 years after anti-Helicobacter pylori treatment. Vrach. 8: 11–14.

12. Jenke ACW. (2012). Human β-defensin 2 expression in ELBW infants with severe necrotizing enterocolitis. Clinical Investigation. 72; 5: 513–520. https://doi.org/10.1038/pr.2012.110

13 Kim MJ, Lee WY, Choe YH. (2015). Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy. Gut and Liver. 9; 3: 370–380. https://doi.org/10.5009/gnl13408; PMid:25071071 PMCid:PMC4413971

14. Nuding S, Gersemann M, Hosaka Y et al. (2013). Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance. PLoS ONE. 8; 9: e73867.

15. Palffy R, Gardlik R, Behuliak M et al. (2009). On the Physiology and Pathophysiology of Antimicrobial Peptides. Mol. Med. 15; 1; 2: 51–59.